DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
PRGO logo

Perrigo Company plc Stock Price

NYSE:PRGO Community·US$1.9b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 27 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

PRGO Share Price Performance

US$13.66
-8.61 (-38.66%)
​
US$16.50
Fair Value
US$13.66
-8.61 (-38.66%)
17.2% undervalued intrinsic discount
US$16.50
Fair Value
Price US$13.66
AnalystConsensusTarget US$16.50
AnalystHighTarget US$20.00
AnalystLowTarget US$14.00
Wed, 3 Jun 26
Fair ValueUS$16.50
Share Pricen/a

PRGO Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$16.5 17.2% undervalued intrinsic discount

PRGO: Profit Margins And Operational Strength Will Support Long-Term Upside Potential

0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$20 31.7% undervalued intrinsic discount

Rising Self-Care Demand And Aging Demographics Will Expand OTC Markets

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$14 2.4% undervalued intrinsic discount

Market Softness Will Constrain Margins While Digital Efforts Improve Outlook

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
PRGO logo
Perrigo
31.7% undervalued intrinsic discount

Rising Self-Care Demand And Aging Demographics Will Expand OTC Markets

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 2 Jul
Read Narrative
PRGO logo
Perrigo
2.4% undervalued intrinsic discount

Market Softness Will Constrain Margins While Digital Efforts Improve Outlook

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 18 Jun
Read Narrative
PRGO logo
Perrigo
17.2% undervalued intrinsic discount

PRGO: Profit Margins And Operational Strength Will Support Long-Term Upside Potential

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 3 Jun
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystHighTarget
PRGO logo

PRGO: Index Shift And CEO Transition Will Shape Future Upside Potential

Fair Value: US$20 31.7% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
PRGO logo

PRGO: Leadership Reset And Infant Nutrition Headwinds Will Shape Future Earnings Power

Fair Value: US$14 2.4% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
PRGO logo

PRGO: Future Upside Will Rely On Infant Nutrition Execution

Fair Value: US$16.5 17.2% undervalued intrinsic discount
13 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Very undervalued average dividend payer.

1 Risk
4 Rewards
View Full Analysis

Perrigo Company plc Key Details

US$4.1b

Revenue

US$2.8b

Cost of Revenue

US$1.4b

Gross Profit

US$3.1b

Other Expenses

-US$1.7b

Earnings

Last Reported Earnings
Jun 27, 2026
Next Reporting Earnings
n/a
-12.27
33.26%
-41.09%
131.2%
View Full Analysis

About PRGO

Founded
1887
Employees
8100
CEO
Albert Manzone
WebsiteView website
www.perrigo.com

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women’s health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Recent PRGO News & Updates

Seeking Alpha • Aug 13

Perrigo: The Rebound Is Just Getting Started

Summary Perrigo Company remains substantially undervalued, with a Buy rating justified by strong income and growth potential. Recent quarterly EPS and revenue beats, coupled with market share gains, signal improving fundamentals despite a soft OTC market. Management's focus on cost control, debt reduction, and dividend growth underpins a compelling 16–21% expected annual total return. Dividend yield above 9% and the potential for multiple expansion support the thesis of doubling capital in five years. Read the full article on Seeking Alpha

Recent updates

No updates

Perrigo Company plc Competitors

TECH logo

Bio-Techne

Symbol: NasdaqGS:TECH
Market cap: US$11.3b
AXSM logo

Axsome Therapeutics

Symbol: NasdaqGM:AXSM
Market cap: US$11.1b
TEM logo

Tempus AI

Symbol: NasdaqGS:TEM
Market cap: US$10.6b
KRYS logo

Krystal Biotech

Symbol: NasdaqGS:KRYS
Market cap: US$10.3b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide